Amundi Portfolio holdings
Amundi, established in 2010 through the merger of Crédit Agricole and Société Générale’s asset management arms, is Europe’s largest asset management firm, headquartered in Paris, France, overseeing €2.2 trillion ($2.3 trillion USD) in assets as of late 2024. Serving institutional clients, financial advisors, and retail investors across 35 countries, Amundi offers a broad spectrum of investment solutions, including active and passive funds, ETFs, and sustainable investing options, with a strong focus on cost efficiency and ESG (environmental, social, governance) principles. The firm’s growth has been fueled by strategic acquisitions, such as Pioneer Investments in 2017 and Lyxor in 2021, enhancing its global reach and expertise in index tracking and alternatives. Majority-owned by Crédit Agricole, Amundi combines French financial heritage with a modern, client-centric approach, maintaining a dominant position in Europe while expanding in Asia and the Americas.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$398M |
| 2 |
Apple
AAPL
|
+$326M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
+$286M |
| 4 |
UnitedHealth
UNH
|
+$267M |
| 5 |
Veralto
VLTO
|
+$265M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Wells Fargo 7.5% Non Cumv Perp Conv
WFC.PRL
|
+$730M |
| 2 |
Meta Platforms (Facebook)
META
|
+$674M |
| 3 |
Costco
COST
|
+$635M |
| 4 |
Amazon
AMZN
|
+$528M |
| 5 |
Expedia Group
EXPE
|
+$491M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 29% |
| 2 | Healthcare | 13.85% |
| 3 | Consumer Discretionary | 11.46% |
| 4 | Financials | 11.04% |
| 5 | Industrials | 7.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1626
PRA Group
PRAA
$648M
| $122K | ﹤0.01% |
5,114
+425
| +9% | +$7.95K |
|
1627
Invesco Leisure and Entertainment ETF
PEJ
$252M
| $122K | ﹤0.01% |
3,002
+1,500
| +100% | +$58K |
|
|
HAYN
1628
DELISTED
Haynes International, Inc.
HAYN
| $122K | ﹤0.01% |
2,299
+389
| +20% | +$18.8K |
|
|
CHS
1629
DELISTED
Chicos FAS, Inc.
CHS
| $120K | ﹤0.01% |
15,871
| – | – |
|
1630
Inovio Pharmaceuticals
INO
$79.8M
| $120K | ﹤0.01% |
+11,607
| New | +$57.3K |
|
1631
B&G Foods
BGS
$285M
| $120K | ﹤0.01% |
11,178
+2,068
| +23% | +$19.1K |
|
|
JHG
1632
DELISTED
Janus Henderson
JHG
| $119K | ﹤0.01% |
3,950
-29
| -0.7% | -$749 |
|
1633
Southside Bancshares
SBSI
$1.02B
| $119K | ﹤0.01% |
3,860
+279
| +8% | +$8.12K |
|
|
ROVR
1634
DELISTED
Rover Group, Inc. Class A Common Stock
ROVR
| $119K | ﹤0.01% |
+10,878
| New | +$92K |
|
1635
Compass Minerals
CMP
$1.24B
| $118K | ﹤0.01% |
5,733
+968
| +20% | +$24.7K |
|
1636
Kinetik
KNTK
$3.71B
| $118K | ﹤0.01% |
3,600
+600
| +20% | +$21K |
|
1637
SPDR Gold Trust
GLD
$131B
| $117K | ﹤0.01% |
625
-200
| -24% | -$36.7K |
|
1638
Monro
MNRO
$525M
| $116K | ﹤0.01% |
4,137
+292
| +8% | +$8.22K |
|
|
SWTX
1639
DELISTED
SpringWorks Therapeutics
SWTX
| $115K | ﹤0.01% |
2,772
| – | – |
|
1640
ProKidney
PROK
$308M
| $114K | ﹤0.01% |
71,843
+16,341
| +29% | +$35K |
|
1641
AMERISAFE
AMSF
$569M
| $113K | ﹤0.01% |
2,439
-1,747
| -42% | -$87.2K |
|
1642
iShares Core MSCI Emerging Markets ETF
IEMG
$149B
| $113K | ﹤0.01% |
2,300
-200
| -8% | -$9.69K |
|
1643
Rocket Pharmaceuticals
RCKT
$348M
| $113K | ﹤0.01% |
3,839
-813
| -17% | -$17.9K |
|
1644
Kelly Services Class A
KELYA
$526M
| $113K | ﹤0.01% |
5,557
-395
| -7% | -$7.84K |
|
1645
Rocket Companies
RKT
$36.9B
| $113K | ﹤0.01% |
8,783
-3,361
| -28% | -$32.2K |
|
1646
Precision BioSciences
DTIL
$188M
| $112K | ﹤0.01% |
+8,521
| New | +$91.9K |
|
|
SLCA
1647
DELISTED
U.S. SILICA HOLDINGS, INC.
SLCA
| $111K | ﹤0.01% |
10,367
+717
| +7% | +$8.5K |
|
|
OMGA
1648
DELISTED
Omega Therapeutics, Inc. Common Stock
OMGA
| $111K | ﹤0.01% |
+26,347
| New | +$53.4K |
|
1649
Vir Biotechnology
VIR
$1.47B
| $111K | ﹤0.01% |
10,863
| – | – |
|
1650
TechTarget
TTGT
$246M
| $110K | ﹤0.01% |
3,151
-270
| -8% | -$7.99K |
|
Similar funds
Amundi's Q4 2023 Portfolio in Review
As of Q4 2023, Amundi held 2,118 positions worth $222B, up 9.2% from $203B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Amundi's Q4 2023 filing shows 107 new, 857 increased, 762 reduced and 120 closed positions. Its largest new stake was Veralto: 3,549,374 shares worth $276M. The largest sale was Wells Fargo 7.5% Non Cumv Perp Conv, an estimated $730M.
By sector, the portfolio is most concentrated in Technology at 29% of assets, up from 28% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Amundi's largest Q4 2023 buy was Veralto: 3,549,374 shares worth $276M.
- Amundi added most to Johnson & Johnson in Q4 2023, an estimated $398M increase.
- Amundi's biggest Q4 2023 reduction was Wells Fargo 7.5% Non Cumv Perp Conv, cutting an estimated $730M.
- Amundi fully exited Activision Blizzard in Q4 2023, selling an estimated $284M.
- Amundi's ten largest holdings make up 23% of its $222B portfolio in Q4 2023.
- Amundi opened 107 new positions and closed 120 in Q4 2023.
- Amundi's portfolio value rose 9.2% quarter-over-quarter to $222B.
Based on Amundi's 13F filing for Q4 2023, filed 14 Feb 2024.